FDA approves Janssen’s twice-yearly antipsychotic for schizophrenia
The approval is based on data from the Phase III trial, where 92.5% of the patients on Invega Hafyera did…
Psychiatric disorders
Latest in
Psychiatric disorders
Major depressive disorder: why does it affect women more?
Major depressive disorder (MDD) is a common mental health disorder that affects more than 264 million people globally, and it…
By
Biogen and Sage Therapeutics to co-develop depression and tremor therapies
Biogen and Sage Therapeutics have entered a global collaboration and licence agreement to jointly develop and commercialise depression and tremor…
Janssen’s esketamine nasal spray not recommended by NICE for NHS use
The UK’s pricing regulator the National Institute for Health and Clinical Excellence (NICE) has decided to not recommend Janssen’s Spravato…
By
FDA approves Secuado patch for Schizophrenia
Secuado is the first and only transdermal patch formulation to be approved for treating schizophrenia.
By
FDA greenlight for esketamine sheds light on ketamine’s potential
In March, the FDA approved Janssen Pharmaceuticals’ depression drug esketamine, a form of ketamine for use as a treatment for…
By
Cost-effectiveness could affect the uptake of Spravato for the treatment of MDD
Spravato is estimated to cost $198,000 per quality-adjusted life year (QALY) gained, exceeding the commonly cited cost-effectiveness thresholds of between…
By
Greater focus on comorbid disorders in PTSD pipeline
PTSD is an indication with limited pharmacological treatment options.
By